Dr Reddy's Q4 result: Net profit rises 22% to ₹1,594 cr, dividend declared

Dr Reddy's Q4 FY25 result: The board of directors have recommended a final dividend of ₹8 per share

dr reddy's laboratory , dr reddy , drl pharma sector

Rahul Goreja New Delhi

2 min read Last Updated : May 09 2025 | 5:49 PM IST

Listen to This Article

Dr Reddy’s Laboratories on Thursday reported a consolidated net profit of ₹1,593.9 crore for the quarter ended March 31, 2025 (Q4 FY25), marking a 22 per cent increase year-on-year (Y-o-Y) from ₹1,307 crore. Sequentially, profit rose 13 per cent from ₹1,413.3 crore. The company said that new product launches played a key role in achieving double-digit growth in the fourth quarter.

Meanwhile, the pharmaceutical major’s consolidated revenue from operations stood at ₹8,506 crore in Q4 FY25, up 20 per cent from ₹7,083 crore in the same quarter last year. Sequentially, revenue grew 2 per cent from ₹8,358.6 crore in Q3 FY25.

Dr Reddy’s FY25 result

For the entire year, net profit grew marginally by 1.5 per cent to ₹5,654.4 crore from ₹5,568.4 crore in FY24. Moreover, revenue from operations increased from ₹27,916.4 crore in FY24 to ₹32,553.5 crore, registering a 16.6 per cent hike.

Dr Reddy’s Q4 result: Dividend declared

The board of directors have recommended a final dividend of Rs 8 per share, subject to approval of shareholders.

"We achieved double-digit growth across our businesses, driven by successful product launches, increased revenues from key products in the US and the integration of the acquired NRT business. We will continue to strengthen and grow our core businesses through portfolio management and operational excellence, while pursuing strategic partnerships and inorganic growth opportunities," GV Prasad, MD and co-chairman of Dr Reddy’s Lab, said.